Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 23, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Jun 23, 2021
CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021,...
-
Jun 9, 2021Presentations featuring data evaluating DAYVIGO in insomnia highlighting the impact for appropriate patients
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new presentations featuring the latest data about the company's insomnia medication DAYVIGO (lemborexant) will be...
Jun 7, 2021Programs now available to support patients and families with their treatment journeyCAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- Following today’s U.S. Food and Drug Administration’s (FDA) accelerated approval of ADUHELMTM (aducanumab-avwa) as...
- Jun 7, 2021The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease
CAMBRIDGE, Mass. and TOKYO, June 7, 2021 (GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted...
-
May 24, 2021
Hackensack Meridian Health, New Jersey's largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a...
-
Apr 19, 2021Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Apr 16, 2021Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeline and portfolio, including Alzheimer's disease, insomnia and...
-
Mar 16, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research...
-
Mar 5, 2021- Oral presentations and posters highlighting Eisai's investigational novel therapies and immunoassay system being studied for Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company's robust Alzheimer's disease (AD) pipeline, including...